Get the Stockscreener App
123.18
1.18%
-1.47
After Hours:
123.33
0.15
+0.12%
State Street Spdr S P Biotech Etf stock is traded at $123.18, with a volume of 6.85M.
It is down -1.18% in the last 24 hours and down -0.61% over the past month.
See More
Previous Close:
$124.65
Open:
$125.16
24h Volume:
6.85M
Relative Volume:
0.70
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.04%
1M Performance:
-0.61%
6M Performance:
+41.72%
1Y Performance:
+36.91%
1-Day Range:
$122.23
$125.61
1-Week Range:
$121.69
$127.05
52-Week Range:
$66.66
$132.09
State Street Spdr S P Biotech Etf Stock (XBI) Company Profile
Name
State Street Spdr S P Biotech Etf
Sector
Industry
Phone
-
Address
-
Compare XBI vs VTI, SPY, IVV, VB, QQQ
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBI
State Street Spdr S P Biotech Etf
|
123.18 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
336.01 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
State Street Spdr S P 500 Etf Trust
|
681.27 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
684.33 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
272.94 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
600.64 | 124.43B | 0 | 0 | 0 | 0.00 |
State Street Spdr S P Biotech Etf Stock (XBI) Latest News
Do Wall Street Analysts Like Incyte Corporation Stock? - FinancialContent
Do financial experts on Wall Street have a favorable opinion of Incyte Corporation shares? - Bitget
Moderna, Mexico Partner To Boost Local Vaccine Production - Benzinga
4,441 Shares in SPDR S&P Telecom ETF $XTL Purchased by Arkadios Wealth Advisors - Defense World
These Three Biotechs Have the Right Mix as the Industry Gains - TheStreet Pro
Vaxcyte Pushes Next-Gen Pneumococcal Vaccine Into Phase 3 Phase - Benzinga
Biotech ETF (XBI) Hits New 52-Week High - TradingView
Where To Invest $100,000: Japan Stocks, AI, Baseball Cards - Bloomberg
Stock Market Today: Dow gains 250 points, S&P 500 and Nasdaq advance after Trump’s Greenland pivot boosts risk appetite - MarketWatch
Moderna Stock Explodes To New 52-Week High: What's Driving The Action? - Benzinga
2025 ETF Wrap-Up And What To Expect In 2026 - Seeking Alpha
Should you invest in the State Street SPDR S&P Biotech ETF (XBI)? - MSN
U.S. Biotech Rebound in 2026: IPOs, Deals & Policy Clarity Drive OptimismNews and Statistics - IndexBox
Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84% - Intellectia AI
US Biotech Share Sales Deliver Biggest First Week Since 2021 - Bloomberg
‘Biotech Super Bowl’ Lands With a Thud. Stocks Slide on Lack of Deal News. - Barron's
Here's Why Biotech ETFs Are Rallying Hard - Yahoo Finance
Equity Markets Rally, Commodities Decline as ETF Investors Optimize Portfolios for 2026 - Bitget
Equities Surge, Commodities Sink As ETF Investors Plan 2026Vanguard S&P 500 ETF (ARCA:VOO) - Benzinga
As Artificial Intelligence Stocks Surge in Value, Health Care ETFs Take Center Stage for Growth - Bitget
As AI Valuations Stretch, Health Care ETFs Step Into The Growth Spotlight - Benzinga
Biotech and pharma stocks tumble as investors race into energy - MSN
Biotech and Pharma Stocks Tumble as Investors Race into Energy - Barron's
Biotech: Time For A Pause To Start 2026 - Seeking Alpha
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - sharewise.com
The Year-End 2025 Biotech Rally And What It Means For 2026 - Benzinga
Chart of the Week: Moderna Stock May Be Finding a Bottom - Barron's
2026 Market Outlook: S&P 500 Looks Expensive, But Biotech Could Outperform Under The Hood - Seeking Alpha
Two Sector ETFs Are Quietly Outperforming the S&P 500 Without a Single AI Stock - MSN
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now? - sharewise.com
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - sharewise.com
Look What I Found While Bargain Hunting in the Biotech Sector - TheStreet Pro
Beyond S&P 500: KKR Flags Asia, Biotech, Infrastructure As Next 'High-Grade' Trades For 2026 - Benzinga
If You Invested $100 In State Street SPDR S&P Biotech ETF Stock 20 Years Ago, You Would Have This Much Today - Benzinga
Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus - Sahm
Why Is Trinity Biotech Stock Soaring Tuesday? - Benzinga
Toast, Uber And More On CNBC's 'Final Trades'Baidu (NASDAQ:BIDU), Lyft (NASDAQ:LYFT) - Benzinga
If These Biotech Stocks Pull Back, I'll Be Ready to Pull the Trigger - TheStreet Pro
Biotech Was ‘En Fuego’ — Now I've Got My Eyes on Another Market Laggard - TheStreet Pro
Should You Invest in the State Street Health Care Select Sector SPDR ETF ETF (XLV)? - MSN
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? - Yahoo Finance
I'm Eyeing One Big, One Little Biotech for a Repeat Trade - TheStreet Pro
Should You Invest in the iShares Biotechnology ETF (IBB)? - sharewise.com
Should State Street SPDR MSCI USA StrategicFactors ETF (QUS) be on your investing radar? - MSN
2 Brilliant Biotech ETFs to Watch in 2026 - AOL.com
Biotech ETFs Gain Momentum with Promising Gains and Risks - cointurk finance
Should you invest in the State Street SPDR S&P Regional Banking ETF (KRE)? - MSN
Should State Street SPDR S&P Dividend ETF (SDY) be on your investing radar? - MSN
Should You Invest in the SPDR S&P Homebuilders ETF (XHB)? - MSN
Eight stock picks to play one of the healthiest corners of the market - MarketWatch
Opinion: The Fed cut rates. Biotech didn’t notice. - MarketWatch
State Street Spdr S P Biotech Etf Stock (XBI) Financials Data
There is no financial data for State Street Spdr S P Biotech Etf (XBI). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):